Abscint
0749.828.410 · rovalta.com · 23/09/2026
ACTIVE
Abscint
Financial year 2025 · closed on 31/12/2025
Net result
363,8 k €
+127.1% YoY
Gross margin
870,8 k €
+231.9% YoY
Equity
5,6 M €
+60.3% YoY
Workforce
2,7 ETP
-10.0% YoY
Overview
What does Abscint do?
Abscint is a Public limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 2,7 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0749.828.410
Incorporation
06/07/2020
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 23
4000 Liège · WallonieSee on map
4000 Liège · WallonieSee on map
Contributed capital
7 248 337,10 €
Latest accounts
31/12/2025
Average workforce
2,7 ETP
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology86901Other human health activities86910Other human health activities72101Research and experimental development on natural sciences and engineering72110Research and experimental development on biotechnology
Joint committees (1)
- 200
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 870,8 k € | +232% | -660,2 k € | -101% | -328,2 k € | -31.4% | -249,7 k € | -98.7% | -125,7 k € |
| EBITDA | 541,2 k € | +152% | -1 M € | -66.7% | -622,2 k € | -43.5% | -433,7 k € | -89.7% | -228,6 k € |
| Operating result | 247,5 k € | +114% | -1,8 M € | +1.5% | -1,8 M € | -285% | -463,5 k € | -94.8% | -237,9 k € |
| Net result | 363,8 k € | +127% | -1,3 M € | -32.4% | -1 M € | -118% | -463,6 k € | -94.9% | -237,9 k € |
| Balance sheet | |||||||||
| Equity | 5,6 M € | +60.3% | 3,5 M € | -22.6% | 4,5 M € | +246% | 1,3 M € | +207% | 422 k € |
| Total assets | 6,8 M € | +60.3% | 4,3 M € | -9.8% | 4,7 M € | +227% | 1,5 M € | +186% | 507,3 k € |
| Cash | 2,8 M € | +29.4% | 2,1 M € | -28.1% | 3 M € | +203% | 985,9 k € | +171% | 364,4 k € |
| Debts | 1,3 M € | +60.6% | 804,4 k € | +212% | 257,5 k € | +67.0% | 154,2 k € | +80.8% | 85,3 k € |
| Other | |||||||||
| Workforce | 2,7 ETP | -10.0% | 3,0 ETP | – | – | – | |||
Estimate
Indicative valuation
As an indication, this company is worth
between 5 M€ and 10 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 6 active · 12 ended
Active mandates
Koen DEWAELE
ActiveActive
Didier Allaer
ActiveJacobus Boonen
ActiveActive
Active
Ended mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
AMPACIMON● Active | 0827.990.317 |
Amyl Therapeutics● Active | 0758.775.372 |
BECARV● Bankrupt | 0840.777.885 |
BE.SPINE● Active | 1013.110.857 |
CEFALY Technology● Active | 0870.578.661 |
DERMAX● Active | 0667.730.677 |
DIANOSIC● Active | 1034.558.646 |
DW Cefaly Holding● Active | 0725.837.241 |
| 1023.778.481 | |
EXO Biologics● Active | 0732.982.379 |
ExoXpert● Active | 1003.807.666 |
Hirundo Biosciences● Active | 0681.855.065 |
HolyFox Invest● Active | 1010.693.181 |
Hyloris● Active | 0669.738.676 |
Hyloris Developments● Active | 0542.737.368 |
Hyloris Pharmaceuticals● Active | 0674.494.151 |
Hyloris Therapeutics● Active | 1025.029.385 |
LEGIAPARK● Active | 0728.589.170 |
MAN & SCIENCE● Active | 0837.403.770 |
ONCORADIOMICS● Active | 0662.719.440 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 03/07/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 18 months |
| Filing date | 06/07/2026 | 19/06/2025 | 17/06/2024 | 26/06/2023 | 01/07/2022 |
| General meeting | 17/06/2026 | 13/06/2025 | 14/06/2024 | 30/05/2023 | 27/06/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
5 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 17/06/2026 | 06/07/2026 | French | |
| Abridged model | 31/12/2024 | 13/06/2025 | 19/06/2025 | French | |
| Micro model | 31/12/2023 | 14/06/2024 | 17/06/2024 | French | |
| Micro model | 31/12/2022 | 30/05/2023 | 26/06/2023 | Dutch | |
| Micro model | 31/12/2021 | 27/06/2022 | 01/07/2022 | Dutch |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 5 M€ and 10 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 6 active · 12 ended
Active mandates
Koen DEWAELE
ActiveActive
Didier Allaer
ActiveJacobus Boonen
ActiveActive
Active
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates21/09/2026Nominations et démissions
- Capital / shares25/08/2026CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION,
- Capital / shares21/11/2025STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates14/02/2025DEMISSIONS, NOMINATIONS
- Capital / shares05/02/2024CAPITAL, ACTIONS
- Other06/10/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Mandates03/10/2023MAATSCHAPPELIJKE ZETEL - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
- Mandates18/11/2022STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025363,8 k €↑
- 2024Annual accounts 2024-1,3 M €↓
- 2023Annual accounts 2023-1 M €↓
- 2022Annual accounts 2022-463,6 k €↓
- 2021Annual accounts 2021-237,9 k €
- 06/07/2020IncorporationPublic limited company